Optimizing drug therapy in frail patients with type 2 diabetes mellitus
| Autor: | Núria Molist-Brunet, Núria Solà-Bonada, Daniel Sevilla-Sánchez, Emma Puigoriol-Juvanteny, M Cruz-Grullón, Joan Espaulella-Panicot, J González-Bueno |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Aging
medicine.medical_specialty Frail Elderly Population Frailty Index 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Internal medicine medicine Humans Frail elderly Prospective Studies 030212 general & internal medicine Medical prescription education Geriatric Assessment Aged Polypharmacy education.field_of_study Frailty business.industry Type 2 Diabetes Mellitus Diabetes Mellitus Type 2 Observational study Geriatrics and Gerontology business 030217 neurology & neurosurgery |
| Zdroj: | Aging Clinical and Experimental Research. 32:1551-1559 |
| ISSN: | 1720-8319 |
| DOI: | 10.1007/s40520-019-01342-z |
| Popis: | Type 2 diabetes mellitus (T2DM) is closely linked with ageing. In frail diabetic patients, the risks of intensive antidiabetic therapy outweigh the potential benefits. To study the prevalence of T2DM in frail elderly patients, to identify inappropriate prescription (IP) of antidiabetic drugs and to study the relationship between patients’ frailty index (FI) with polypharmacy and IP. This was a prospective, descriptive, observational study of elderly patients. Each patient’s antidiabetic treatment was analysed by applying the patient-centred prescription model (PCP), which centres therapeutic decisions on the patient’s global assessment and individual therapeutic goal. 210 patients with T2DM were included (25.15% prevalence). They were characterised by high multimorbidity and frailty. 93.3% presented polypharmacy and 51% excessive polypharmacy. IP was identified in 66.2% of patients. A statistically significant relationship was found between the progression in FI degree and IP prevalence (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink